Accelerating Tumor Drug Translation: All-in-One Preclinical ETESTM Platform
Leveraging endogenous T-cell signaling redirection technology, our preclinical services overcome CAR-T limitations in solid tumors.
Learn More
Leveraging endogenous T-cell signaling redirection technology, our preclinical services overcome CAR-T limitations in solid tumors.
Learn More
Modular ETESTM constructs are precisely designed to engage endogenous T-cell signaling for targeted tumor attack.
ETESTM constructs are efficiently introduced into T cells using optimized gene delivery strategies to ensure stable expression.
Engineered T cells are expanded and formulated under controlled conditions to meet preclinical quality standards.
Functional activity of ETESTM T cells is evaluated through cytotoxicity assays, cytokine profiling, and tumor cell killing in co-culture systems.
Preclinical models are used to assess anti-tumor efficacy, T-cell persistence, and safety profiles in vivo.
ETES enables precise targeting of leukemias and lymphomas, driving potent cytotoxic activity while minimizing cytokine release, making it well-suited for sensitive blood cancer applications.
Designed to overcome barriers such as poor T-cell infiltration and immunosuppressive microenvironments, ETES promotes localized, durable responses against a wide range of solid tumors.
ETES reactivates immune responses in tumors lacking co-stimulatory signals or T-cell presence, transforming cold tumors into immune-responsive targets through controlled endogenous engagement.
Alfa Cytology is a preclinical solution provider powering next-generation tumor immunotherapies through our proprietary ETESTM Platform, leveraging several years of expertise to accelerate drug development from target validation to IND submission with globally compliant solutions.
Scientific Excellence
Customized Solutions
Collaborative Approach
Data
Security
ETESTM leverages endogenous signaling pathways to achieve more natural and controlled T-cell activation.
By avoiding excessive artificial stimulation, ETESTM minimizes the risk of cytokine release syndrome.
ETESTM functions independently of external TCRs or CAR domains, enhancing cellular stability and safety.
ETESTM is adaptable to both hematologic malignancies and solid tumors, including those with immunosuppressive microenvironments.
The ETESTM architecture allows plug-and-play customization to match specific tumor targets and signaling needs.
ETESTM simplifies the genetic engineering workflow, reducing complexity in vector design and cell production.
The ETESTM Platform is a modular T-cell activation system developed for next-gen immunotherapy. Alfa Cytology offers full preclinical development services to support your pipeline.
Copyright © 2025 Alfa Cytology. All rights reserved.